These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 11934227)

  • 21. Antigen encoded by vaccine vectors derived from human adenovirus serotype 5 is preferentially presented to CD8+ T lymphocytes by the CD8α+ dendritic cell subset.
    Suleman M; Galea S; Gavard F; Merillon N; Klonjkowski B; Tartour E; Richardson J
    Vaccine; 2011 Aug; 29(35):5892-903. PubMed ID: 21723900
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 'Dressed for success' C-type lectin receptors for the delivery of glyco-vaccines to dendritic cells.
    Unger WW; van Kooyk Y
    Curr Opin Immunol; 2011 Feb; 23(1):131-7. PubMed ID: 21169001
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo.
    Paglia P; Chiodoni C; Rodolfo M; Colombo MP
    J Exp Med; 1996 Jan; 183(1):317-22. PubMed ID: 8551239
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Understanding the murine cutaneous dendritic cell network to improve intradermal vaccination strategies.
    Ginhoux F; Ng LG; Merad M
    Curr Top Microbiol Immunol; 2012; 351():1-24. PubMed ID: 21058006
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Designing oral vaccines targeting intestinal dendritic cells.
    Devriendt B; De Geest BG; Cox E
    Expert Opin Drug Deliv; 2011 Apr; 8(4):467-83. PubMed ID: 21375470
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dendritic cells, but not macrophages or B cells, activate major histocompatibility complex class II-restricted CD4+ T cells upon immune-complex uptake in vivo.
    de Jong JM; Schuurhuis DH; Ioan-Facsinay A; Welling MM; Camps MG; van der Voort EI; Huizinga TW; Ossendorp F; Verbeek JS; Toes RE
    Immunology; 2006 Dec; 119(4):499-506. PubMed ID: 16995881
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The use of dendritic cells for peptide-based vaccination in cancer immunotherapy.
    Salem ML
    Methods Mol Biol; 2014; 1139():479-503. PubMed ID: 24619701
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses.
    Rosalia RA; Cruz LJ; van Duikeren S; Tromp AT; Silva AL; Jiskoot W; de Gruijl T; Löwik C; Oostendorp J; van der Burg SH; Ossendorp F
    Biomaterials; 2015 Feb; 40():88-97. PubMed ID: 25465442
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of antibodies and carbohydrates to target vaccines to human dendritic cells via DC-SIGN.
    Cruz LJ; Tacken PJ; Pots JM; Torensma R; Buschow SI; Figdor CG
    Biomaterials; 2012 Jun; 33(16):4229-39. PubMed ID: 22410170
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dendritic cell-based cancer vaccination: quo vadis?
    Dauer M; Schnurr M; Eigler A
    Expert Rev Vaccines; 2008 Sep; 7(7):1041-53. PubMed ID: 18767953
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Dendritic cell-based therapeutic cancer vaccines].
    Rizzo M; Alaniz L; Mazzolini GD
    Medicina (B Aires); 2016; 76(5):307-314. PubMed ID: 27723619
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dendritic cell targeted vaccines: Recent progresses and challenges.
    Chen P; Liu X; Sun Y; Zhou P; Wang Y; Zhang Y
    Hum Vaccin Immunother; 2016 Mar; 12(3):612-22. PubMed ID: 26513200
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeted antigen delivery and activation of dendritic cells in vivo: steps towards cost effective vaccines.
    Tacken PJ; Figdor CG
    Semin Immunol; 2011 Feb; 23(1):12-20. PubMed ID: 21269839
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting glycan modified OVA to murine DC-SIGN transgenic dendritic cells enhances MHC class I and II presentation.
    Singh SK; Stephani J; Schaefer M; Kalay H; García-Vallejo JJ; den Haan J; Saeland E; Sparwasser T; van Kooyk Y
    Mol Immunol; 2009 Dec; 47(2-3):164-74. PubMed ID: 19818504
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lymph node targeting strategies to improve vaccination efficacy.
    Jiang H; Wang Q; Sun X
    J Control Release; 2017 Dec; 267():47-56. PubMed ID: 28818619
    [TBL] [Abstract][Full Text] [Related]  

  • 36. DNA vaccination: antigen presentation and the induction of immunity.
    Shedlock DJ; Weiner DB
    J Leukoc Biol; 2000 Dec; 68(6):793-806. PubMed ID: 11129646
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nanogel vaccines targeting dendritic cells: contributions of the surface decoration and vaccine cargo on cell targeting and activation.
    Thomann-Harwood LJ; Kaeuper P; Rossi N; Milona P; Herrmann B; McCullough KC
    J Control Release; 2013 Mar; 166(2):95-105. PubMed ID: 23220107
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting interferon-alpha to dendritic cells enhances a CD8
    Graham JP; Authie P; Karolina Palucka A; Zurawski G
    Vaccine; 2017 Aug; 35(35 Pt B):4532-4539. PubMed ID: 28743486
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nanocarriers targeting dendritic cells for pulmonary vaccine delivery.
    Kunda NK; Somavarapu S; Gordon SB; Hutcheon GA; Saleem IY
    Pharm Res; 2013 Feb; 30(2):325-41. PubMed ID: 23054093
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phagocytosis of synthetic particulate vaccine delivery systems to program dendritic cells.
    Thiele L; Merkle HP; Walter E
    Expert Rev Vaccines; 2002 Aug; 1(2):215-26. PubMed ID: 12901560
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.